Final results of a phase I trial of fasting prior to platinum-based chemotherapy.

被引：0
|
作者：
Quinn, David I.
Groshen, Susan G.
Shah, Manali
Tsao-Wei, Denice D.
Garcia, Agustin A.
Huyen Pham
Lin, Yvonne Gail
Ketchens, Charlean
Massopust, Kristy
Wei, Min
Longo, Valter
Dorff, Tanya B.
机构：
[1] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[2] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[3] Univ So Calif, Los Angeles, CA USA
[4] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] USC Davis Sch Gerontol, Los Angeles, CA USA
[6] Univ So Calif, Sch Gerontol, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9632
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
    Baka, S.
    Califano, R.
    Ferraldeschi, R.
    Aschroft, L.
    Thatcher, N.
    Taylor, P.
    Faivre-Finn, C.
    Blackhall, F.
    Lorigan, P.
    BRITISH JOURNAL OF CANCER, 2008, 99 (03) : 442 - 447
  • [32] Peripheral neurotoxicity of platinum-based chemotherapy
    Cavaletti, Guido
    NATURE REVIEWS CANCER, 2008, 8 (01) : 72 - 72
  • [33] Peripheral neurotoxicity of platinum-based chemotherapy
    Guido Cavaletti
    Nature Reviews Cancer, 2008, 8 : 72 - 72
  • [34] A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
    Trillsch, Fabian
    Schochter, Fabienne
    Park-Simon, Tjoung-Won
    Reuss, Alexander
    Fehm, Tanja N.
    Wimberger, Pauline
    Bronger, Holger
    Schmalfeldt, Barbara
    Sehouli, Jalid
    Marme, Frederik
    Heitz, Florian
    Mahner, Sven
    Fredrich, Michaela
    Barth, Stefanie
    Stec, James Joseph
    Method, Michael W.
    Harter, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
    S Baka
    R Califano
    R Ferraldeschi
    L Aschroft
    N Thatcher
    P Taylor
    C Faivre-Finn
    F Blackhall
    P Lorigan
    British Journal of Cancer, 2008, 99 : 442 - 447
  • [36] The resurgence of platinum-based cancer chemotherapy
    Lloyd Kelland
    Nature Reviews Cancer, 2007, 7 : 573 - 584
  • [37] Final results of a phase II trial of S-1 with biweekly docetaxel for non-small cell lung cancer previously treated with platinum-based chemotherapy (NJLCG0701)
    Ishimoto, O.
    Sakakibara, T.
    Maemondo, M.
    Morikawa, N.
    Okudera, K.
    Usul, K.
    Suzuki, T.
    Inoue, A.
    Nukiwa, T.
    Sugawara, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial
    Ettinger, D. S.
    Jotte, R.
    Lorigan, P.
    Gupta, V.
    Garbo, L.
    Spigel, D.
    Dudek, A. Z.
    Salgia, R.
    McNally, R.
    Renschler, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 541 - 541
  • [39] The prognostic impact of bone metastasis in urothelial carcinoma treated with first-line platinum-based chemotherapy.
    Alqaisi, Husam
    Veitch, Zachary William Neil
    Stecca, Carlos
    Kaiser, Jeenan
    North, Scott A.
    Samnani, Sunil
    Alimohamed, Nimira S.
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [40] Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
    Leu, KM
    Kim, KM
    Larson, M
    Larson, M
    Schiller, JH
    LUNG CANCER, 2001, 34 (01) : 105 - 113
12345